Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors

References

• de Ruijter AJM, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737–49
   PubMed Web of Science ®Google Scholar
• Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10:32–42
   PubMed Web of Science ®Google Scholar
• Gregoretti I, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17–31
   PubMed Web of Science ®Google Scholar
• Yang XJ, Grégoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005;25:2873–84
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30–9
   PubMed Web of Science ®Google Scholar
• Lee H-Z, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 2015;21:2666–70
   PubMed Web of Science ®Google Scholar
• Stubbs MC, Kim W, Bariteau M, et al. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin Cancer Res 2015;21:2348–58
   PubMed Web of Science ®Google Scholar
• Colarossi L, Memeo L, Colarossi C, et al. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Proteomics Clin Appl 2014;8:924–31
   PubMed Web of Science ®Google Scholar
• Kang ZH, Wang CY, Zhang WL, et al. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS One 2014;9:e98894
   PubMed Web of Science ®Google Scholar
• Govindarajan N, Rao P, Burkhardt S, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease. EMBO Mol Med 2013;5:52–63
   PubMed Web of Science ®Google Scholar
• Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2010;35:870–80
   PubMed Web of Science ®Google Scholar
• Simões-Pires CA, Zwick V, Nurisso A, et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener 2013;8:7
   PubMed Web of Science ®Google Scholar
• Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 2013;5:344–52
   PubMed Web of Science ®Google Scholar
• Lee P, Murphy B, Miller R, et al. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res 2015;35:615–25
   PubMed Web of Science ®Google Scholar
• Subramanian S, Bates SE, Wright JJ, et al. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010;3:2751–67
   Google Scholar
• Parmigiani RB, Xu WS, Venta-Perez G, et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci USA 2008;105:9633–8
   PubMed Web of Science ®Google Scholar
• Chen S, Owens GC, Makarenkova H, Edelman DB. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 2010;5:e10848
   PubMed Web of Science ®Google Scholar
• Heltweg B, Dequiedt F, Marshall BL, et al. Subtype selective substrates for histone deacetylases. J Med Chem 2004;47:5235–43
   PubMed Web of Science ®Google Scholar
• Heltweg B, Trapp J, Jung M. In vitro assays for the determination of histone deacetylase activity. Methods 2005;36:332–7
   PubMed Web of Science ®Google Scholar
• Wegener D, Wirsching F, Riester D, Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 2003;10:61–8
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Jung M, Brosch G, Loidl P. A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res 1999;27:2057–8
   PubMed Web of Science ®Google Scholar
• Greis KD. Mass spectrometry for enzyme assays and inhibitor screening: an emerging application in pharmaceutical research. Mass Spectrom Rev 2007;26:324–39
   PubMed Web of Science ®Google Scholar
• Kelly RD, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 2013;41:741–9
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Nakayama JI. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotechnol 2011;2011:129383
   PubMedGoogle Scholar
• Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29:255–65
   PubMed Web of Science ®Google Scholar
• Milli A, Perego P, Beretta GL, et al. Proteomic analysis of cellular response to novel proapoptotic agents related to atypical retinoids in human IGROV-1 ovarian carcinoma cells. J Proteome Res 2011;10:1191–207
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581–9
   PubMed Web of Science ®Google Scholar
• Kim IA, Kim JH, Shin JH, et al. A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells. Cancer Res Treat 2005;37:122
   PubMedGoogle Scholar
• Haggarty SJ, Koeller KM, Wong JC, et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003;100:4389–94
   PubMed Web of Science ®Google Scholar
• Grozinger CM, Chao ED, Blackwell HE, et al. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001;276:38837–43
   PubMed Web of Science ®Google Scholar
• Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010;132:10842–6
   PubMed Web of Science ®Google Scholar
• Cheng F, Lienlaf M, Wang HW, et al. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol 2014;193:2850–62
   PubMed Web of Science ®Google Scholar
• Gradilone SA, Habringer S, Masyuk TV, et al. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol 2014;184:600–8
   PubMed Web of Science ®Google Scholar
• Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem 2013;288:14400–7
   PubMed Web of Science ®Google Scholar
• Glaser KB, Li J, Pease LJ, et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem Biophys Res Commun 2004;325:683–90
   PubMed Web of Science ®Google Scholar
• Inoue S, Mai A, Dyer MJS, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006;66:6785–92
   PubMed Web of Science ®Google Scholar